In September 2023, CDC's Advisory Committee on Immunization Practices recommended updated 2023-2024 (monovalent XBB.1.5) COVID-19 vaccination for all persons aged =6 months to prevent COVID-19, including severe disease. As with past COVID-19 vaccines, additional doses may...
Number of new coronavirus (COVID-19) cases in Europe 2023 Published by Juliette Gagliardi, Dec 10, 2024 As of January 13, 2023, there have been 270,744,353 confirmed cases of coronavirus (COVID-19) across the whole of Europe since the first confirmed cases in January 2020. There were...
On July 28, 2024, the coronavirus death toll stood at over 168,000 deaths in France. The cumulative number of deaths in France attributed to COVID-19 increased especially in the winter season 2020-2021. For further information about the coronavirus (COVID-19) pandemic, please visit our dedic...
Novavax Covid-19疫苗于2022年2月14日在新加坡首次获得临时授权。 今年5月,卫生部还宣布将向12至17岁的青少年提供Novavax疫苗,此前卫生科学管理局批准该疫苗用于这一年龄组。 卫生部在10月的最新咨询中还指出,鼓励6个月及以上的人在2023年或2024年额外接种一剂Covid-19疫苗。中央社...
Kunzmann K. COVID-19 Cases Are Climbing, with Donald Alcendor, PhD. HCPLive. Published September 1, 2023. https://www.hcplive.com/view/covid-19-cases-climbing-donald-alcendor-phd HCPLive Year in Review: Top Podcasts & Shows for 2024 ...
据调研机构恒州诚思(YH Research)研究统计,2023年全球COVID-19 抗原自检试剂盒市场规模约 亿元,2019-2023年年复合增长率CAGR约为%,预计未来将持续保持平稳增长的态势,到2030年市场规模将接近 亿元,未来六年CAGR为 %。 2024年10月恒州诚思(YHResearch)调研团队最新发布的《2024年全球及中国COVID-19 抗原自检试剂...
过山车之痛随着COVID-19红利的逐渐消退，辉瑞也未能幸免，其销售预测显示出持续下滑的趋势。在12月中旬的电话会议中，辉瑞首席财务官David Denton坦言，由于“COVID-19组合前景存在固有的可变性”，2024年Comirnaty的销售预测已设定为低于假设的疫苗接种率，预计收入将仅为约80亿美元。与此同时，辉瑞首席执行官Albert ...
国际血栓与止血学会近期发布了首个《国际血栓与止血学会COVID-19抗血栓治疗指南》,针对不同临床环境中的COVID-19患者提供抗凝和抗血小板药物的建议,其目标受众包括内科、重症监护、传染病、血液学和血管内科的临床医生,以及为COVID-19患者提供住院或门诊护理的住院医生、家庭医生和其他卫生保健提供者。笔者现就该指南的...
This reformulation is why health officials are calling this year's shots the "2023-2024 COVID-19 vaccine" or simply the "updated COVID-19 vaccine" —no longer using the word "boosters,"like additional doses have been called in previous rollouts. ...
Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula)* is FDA authorized under Emergency Use Authorization (EUA) to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 6 months through 11 years of...